We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Molecular Transplant Diagnostics Market to Triple Revenue

By LabMedica International staff writers
Posted on 09 May 2017
The global market for molecular transplant diagnostics is estimated to be over USD 300 million and is projected to grow at an average annual rate of 9% up to 2021. These are the latest findings of Kalorama Information, an independent medical market research firm.

Molecular testing technologies are well suited for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants, which require histocompatibility between the recipient and donor for successful outcomes. The various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and HSCT or bone marrow transplants; post-transplant monitoring including for transplant rejection is an ancillary testing area. Allogenic HSCT transplantation is a comparatively high growth procedure area in comparison to solid organ transplantation and is a leading area of application for molecular HLA typing.

Image: The global market for molecular transplant diagnostics is projected to grow at an average annual rate of 9% up to 2021 (Photo courtesy of Kalorama Information).
Image: The global market for molecular transplant diagnostics is projected to grow at an average annual rate of 9% up to 2021 (Photo courtesy of Kalorama Information).

Over allogenic 9,000 HSCTs and approximately 30,000 solid organ transplants are performed in the US each year, making it the world’s largest market for molecular transplant diagnostics. The large size of the US molecular transplant diagnostics market is sustained by the demand for high resolution molecular HLA typing, including sequencing-based methods. In Europe, over 30,000 solid organ transplants and around 18,000 HSCTs are performed each year with transplant volumes in the region continuing to grow at a faster pace as compared to the US. This is due to the higher number of solid organ transplants and HSCTs being performed in the Eastern European countries and other less mature markets, thereby driving sales of test products.

"Molecular is not ubiquitous, as some forecasters – including us- may have thought a decade ago," said Bruce Carlson, Publisher of Kalorama Information. "It performs well in areas where it is set apart from other technologies. HLA is a value-add area for molecular, and you see that in the growth rate."


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests